Bright Minds Biosciences (DRUG) Total Current Liabilities (2021 - 2026)

Bright Minds Biosciences' Total Current Liabilities history runs 6 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• Quarterly Total Current Liabilities rose 528.6% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 528.6% YoY) and the FY2025 annual result came in at $1.7 million, up 337.87% from the prior year.
• Total Current Liabilities was $2.8 million for Q1 2026 at Bright Minds Biosciences, up from $1.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $2.8 million in Q1 2026 and bottomed at $209499.0 in Q3 2023.
• A 5-year average of $852827.6 and a median of $490603.7 in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities sank 81.44% — and 2026, when it surged 528.6%.
• Bright Minds Biosciences' Total Current Liabilities stood at $389049.9 in 2022, then plunged by 46.15% to $209499.0 in 2023, then jumped by 57.7% to $330380.1 in 2024, then surged by 243.49% to $1.1 million in 2025, then jumped by 146.28% to $2.8 million in 2026.
• Business Quant data shows DRUG's Total Current Liabilities at $2.8 million in Q1 2026, $1.1 million in Q4 2025, and $1.7 million in Q3 2025.